secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zenas BioPharma, Inc. (ZBIO)
CIK:        0001953926
Form:       8-K
Filed at:   2025-02-05T23:59:59+00:00
Accession:  0001104659-25-009368
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zenas BioPharma reports preliminary $350M cash; key obexelimab trial readouts in 2025
--------------------------------------------------------------------------------

- Preliminary unaudited cash, equivalents, and short-term investments ~$350M as of Dec 31, 2024; expected to fund ops into Q4 2026.
- Phase 3 INDIGO trial (IgG4-RD) enrollment complete; topline results expected year-end 2025.
- Phase 2 MoonStone (RMS) 12-week primary endpoint results expected Q3 2025; Phase 2 SunStone (SLE) enrollment to finish in 2025.
- Out-licensed thyroid eye disease programs (ZB001) to Zai Lab for Greater China; received upfront fee plus milestones and royalties.
- Raised ~$458.7M in aggregate gross proceeds from Series C and IPO to fund obexelimab development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1953926/000110465925009368/0001104659-25-009368-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1953926/000110465925009368/tm255498d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-009368

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer